BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsEarnings

- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Related news

ARWRArrowhead Pharmaceuticals2026-04-20 20:01 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

ETONEton Pharmaceuticals2026-08-03 10:50 EST

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

ETONEton Pharmaceuticals2026-05-14 20:05 EST

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

KRYSKrystal Biotech2026-08-03 11:00 EST

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

RAREUltragenyx Pharmaceutical2026-07-28 20:05 EST

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

ARWRArrowhead Pharmaceuticals2026-08-03 20:30 EST

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWRArrowhead Pharmaceuticals2026-07-27 11:30 EST

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Stock data

Close
85.83 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States